Pharmaceutical giant GSK has agreed to acquire US cancer drug firm Nuvalent in a deal valued at 10.6 billion US dollars (£8 billion), as the company seeks to strengthen its cancer treatment portfolio.
Deal Details
The UK-based pharmaceutical group will pay 124 US dollars (£92.71) per share for Nasdaq-listed Nuvalent, which is headquartered in Cambridge, Massachusetts. This acquisition is believed to be GSK's largest transaction in over a decade.
GSK stated that the acquisition would allow it to add three products targeting lung cancer in a single transaction, with two of these products currently under review by the US Food and Drug Administration (FDA) for potential approval.
Pipeline Strengthening
Nuvalent has two experimental lung cancer treatments in late-stage development: zidesamtinib and neladalkib. These are designed to treat different forms of non-small cell lung cancer.
GSK chief executive Luke Miels, who assumed the role in January, commented on the acquisition: "Nuvalent's two lead products are potential best-in-class assets that could launch this year if approved by the FDA and offer significant new treatment options to patients with two forms of non-small cell lung cancer."
He added: "The acquisition provides GSK with immediate new sales growth opportunities, improving profit contributions from 2027, and a platform in lung cancer for rapid expansion."
Financial Impact
GSK expects the deal to cost approximately 9.4 billion dollars (£7.1 billion) on a net basis, as Nuvalent brings cash with it. The acquisition is projected to contribute to revenue growth from 2027 and support GSK's target of achieving more than £40 billion in sales by 2031.
Additionally, the deal will help sustain earnings following the loss of patent protection for HIV drug dolutegravir between 2028 and 2030, according to GSK.
Executive Perspectives
James Porter, chief executive of Nuvalent, expressed enthusiasm about the acquisition: "Since our founding, we have leveraged our deep expertise in chemistry and structure-based drug design to develop a portfolio of novel, potentially best-in-class kinase inhibitors."
He continued: "Our close collaboration with leading physician-scientists and patient advocates has driven remarkable enrolment, accelerating development and building confidence in the clinical profile of these drugs. We're excited that GSK has recognised the significant value these programmes can offer patients and shares our vision for practice-changing innovation."
